TRCT
CNSP icon

Tower Research Capital (TRC)’s CNS Pharmaceuticals CNSP Stock Holding History

Tower Research Capital (TRC)’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82K Sell
799
-511
-39% -$2.15K ﹤0.01% 4468
2026
Q1 		$3.13K Buy
+1,310
New +$5.43K ﹤0.01% 4361
2025
Q3 		– Sell
-562
Closed -$5.56K – 5264
2025
Q2 		$5.56K Buy
562
+136
+32% +$1.7K ﹤0.01% 4173
2025
Q1 		$6.95K Buy
+426
New +$20.8K ﹤0.01% 3998
2024
Q4 		– Sell
-27
Closed -$2.13K – 5725
2024
Q3 		$2.13K Buy
+27
New +$7.75K ﹤0.01% 5046
2024
Q2 		– Hold
0
– – – 5419
2024
Q1 		– Hold
0
– – – 5037
2023
Q4 		– Hold
0
– – – 4888
2023
Q3 		– Hold
0
– – – 4724
2023
Q2 		– Hold
0
– – – 4952
2023
Q1 		– Hold
0
– – – 4060
2022
Q4 		– Hold
0
– – – 3795
2022
Q3 		– Hold
0
– – – 4995
2022
Q2 		– Hold
0
– – – 4662
2022
Q1 		– Hold
0
– – – 4288
2021
Q4 		– Hold
0
– – – 4539

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Tower Research Capital (TRC)'s CNSP Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its CNS Pharmaceuticals (CNSP) stake by 39% in Q2 2026, selling an estimated $2.15K and leaving 799 shares worth $3.82K. The position accounts for ﹤0.01% of the portfolio, ranked #4468.

Tower Research Capital (TRC) first reported a position in CNSP in Q3 2024 and has held it in 5 quarters since. The position peaked at $6.95K in Q1 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Tower Research Capital (TRC) held 799 shares of CNS Pharmaceuticals worth $3.82K as of Q2 2026.
  • Tower Research Capital (TRC) sold 511 CNS Pharmaceuticals shares in Q2 2026, an estimated $2.15K.
  • CNS Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4468 holding.
  • Tower Research Capital (TRC) first reported a position in CNS Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s CNS Pharmaceuticals position peaked at $6.95K in Q1 2025.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.